Evidence map›Paper›PMID 40175924›Full record

ArticleInternational journal of emergency medicine2025

Small cell lung cancer case report: acute tumor lysis syndrome after chemotherapy and management strategies for high-risk patients.

Ying Han, Peng Yue, Zuguo Yuan

Abstract read
In one paragraph

Article in International journal of emergency medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ying Han *The Cancer Radiotherapy and Chemotherapy Center of the People's Hospital Affiliated to Ningbo University, Ningbo City, Zhejiang, China. Dr.han@vip.163.com.
Peng Yue *Zhuhai Hospital of Traditional Chinese and Western Medicine, Zhuhai City, Guangdong, China.
Zuguo YuanThe Cancer Radiotherapy and Chemotherapy Center of the People's Hospital Affiliated to Ningbo University, Ningbo City, Zhejiang, China.

Funding

This work was supported by the 2021 Yinzhou District Agriculture and Social Development Project 2021AS0018
6 · The paper itself

Abstract

backgroundIn the treatment of small cell lung cancer (SCLC), acute tumor lysis syndrome (ATLS) is one of the oncologic emergencies that requires particular attention. Previous studies have generally indicated that ATLS increases mortality risk during treatm ent. Therefore, early identification of ATLS, along with proactive prevention and symptomatic management, is particularly crucial.

methodsIn this report, we detail the clinical management of a patient with SCLC and multiple metastases who was identified as being at relatively high risk for ATLS due to a large tumor burden and concurrent liver and kidney dysfunction.

resultsDespite rapid tumor progression, the treatment team implemented aggressive hydration and urine alkalinization as pretreatment measures and personalized dose-reduced chemotherapy based on the standard EC regimen. Nevertheless, the patient developed ATLS, which progressed rapidly, and despite intensive treatment, the condition remained irreversible.

conclusionThis case highlights that in some SCLC patients, pre-chemotherapy evaluation reveals a higher risk for tumor lysis syndrome, and adjusting treatment strategies for these patients requires further investigation. This suggests that managing such high-risk patients in clinical practice requires more cases and optimized treatment strategies to guide management. Therefore, this case is presented to offer insights into this perspective. CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

Acute renal failureHyperuricemiaSmall cell lung cancerTumor Lysis syndrome

Identifiers

PMID40175924
PMCPMC11963435

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.